Candel Therapeutics

Candel Therapeutics is a clinical stage biopharmaceutical company headquartered in Needham, Massachusetts. The company employs 64 people and has generated $2 million in revenue. Candel Therapeutics specializes in developing off-the-shelf multimodal biological immunotherapies designed to trigger a personalized, systemic anti-tumor immune response to combat cancer. Their therapeutic approach centers around two distinct clinical-stage platforms: one based on genetically modified adenovirus and the other on herpes simplex virus (HSV) gene constructs. The company's lead product candidate from the HSV platform, CAN-3110, is currently undergoing an investigator-sponsored phase 1 clinical trial for recurrent high-grade glioma (HGG). Additionally, Candel's enLIGHTEN™ Discovery Platform leverages human biology and advanced analytics to develop novel viral immunotherapies for solid tumors. Their lead candidate from the adenovirus platform, CAN-2409, is actively participating in ongoing clinical trials for non-small cell lung cancer, borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. For more information about Candel Therapeutics, visit www.candeltx.com or contact the company at [email protected].